ArticleEvidence-based complementary and alternative medicine : eCAM2022
A Treatment to Cure Diabetes Using Plant-Based Drug Discovery.
Article in Evidence-based complementary and alternative medicine : eCAM, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 14 citations in OpenAlex.
- Bioactive Peptides from Andean Crops: Lactic Acid Bacteria Fermentation, Complementary Proteolysis, and Biological Activities.Foods (Basel, Switzerland) · 2026Review
- Systematic Optimization Enables Near-Perfect In Vitro Transformation Efficiencies forbioRxiv : the preprint server for biology · 2025Article
- Beyond Green: The Therapeutic Potential of Chlorophyll and Its Derivatives in Diabetes Control.Nutrients · 2025Review
- Bioprospection of indigenous herbal formulations for diabetes care: in vitro, network pharmacology, and molecular dynamics studies.BMC complementary medicine and therapies · 2025Article
- Leiurus quinquestratus venom promotes β islets regeneration and restores glucose level in streptozotocin induced type 2 diabetes mellitus in rats.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The field of peptides and proteins has opened up new doors for plant-based medication development because of analytical breakthroughs. Enzymatic breakdown of plant-specific proteins yields bioactive peptides. These plant-based proteins and peptides, in addition to their in vitro and vivo outcomes for diabetes treatment, are discussed in this study. The secondary metabolites of vegetation can interfere with the extraction, separation, characterization, and commercialization of plant proteins through the pharmaceutical industry. Glucose-lowering diabetic peptides are a hot commodity. For a wide range of illnesses, bioactive peptides from flora can offer up new avenues for the development of cost-effective therapy options.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.